The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Dublin firm Matheson Ormsby Prentice has bolstered its life sciences group with the hire of Tom Mahr, vice-president of legal affairs at pharmaceutical giant Elan.
Mahr, who was a lawyer at Mathesons’ Dublin rival A&L Goodbody prior to his seven-year stint at Elan, will head the firm’s life sciences group.
Ireland’s top firms rarely recruit in-house partner laterals and Mahr is certainly the first major hire from the pharmaceutical sector.
The hire is something of a coup, as Mahr is a heavyweight corporate lawyer who has guided Elan through several large M&A deals. Elan recently sold off its European sales business to Madeus for $120m (£63.4m).
Mathesons’ key pharmaceutical sector clients include Galen, Yamanouchi and Pfizer. Elan has already instructed the firm on smaller matters, but its main corporate adviser until now has been A&L Goodbody.
Life sciences are crucial for Irish firms, with 17 out of 20 of the world’s healthcare groups holding operations in Ireland, mainly due to the country’s advantageous tax regime.